Team:Washington/Gram Negative/Build

From 2010.igem.org

(Difference between revisions)
(Why induce tse2 expression only when a gram-negative pathogen is present?)
(Engineering the Toxin Antitoxin HSL-inducible circuit)
 
(91 intermediate revisions not shown)
Line 26: Line 26:
<!---------------------------------------PAGE CONTENT GOES BELOW THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES BELOW THIS---------------------------------------->
-
=Header 1=
 
-
==Why induce tse2 expression only when a gram-negative pathogen is present?==
+
=Recombineering the Promoter Region of the Type VI Secretion System=
-
<b>A type six secretion system +/Tse2 + strain of ''E. coli'' could be administered like a traditional antibiotic after a pathogen infection by having a strain that constitutively expresses Tse2 and Tsi2. However, this would be a fairly brute force method of anti-bacterial comparable to traditional chemical antibiotics in its damage to the gut’s natural flora, and is only advantage over chemical antibiotics would be the current lack of Tse2 resistant pathogenic bacterial strains. If Tse2 expression is induced by a chemical signal indicative of the presence of a pathogen, any unintended disruption of the natural gut flora will be limited to the area infected with pathogens, and the risk of Tse2 resistance would decrease.</b>
+
[[Image:Washington_Recombineering_basic.png|750px|center|thumb|Schematic Showing the Engineering of the Fosmid to Contain a Divergent T7 Promoter Instead of the Native ''Pseudomonas'' Promoter]]
 +
Our goal was to replace the native ''P. aeruginosa'' regulation of the Type VI Secretion System with one that can be utilized by the ''E. coli'' transcriptional machinery.  In order to replace the native promoters with more robust T7 promoters we used a technique called [https://2010.igem.org/Team:Washington/Protocols/Recombineering Recombineering] to flip out the region containing both promoters and replace it with a gene cassette as follows.  We designed primers to create a cassette using PCR, containing the ''galK'' galactose metabolism gene flanked by 50 base pairs of homology just outside of the promoter region in the fosmid. The cassette was inserted, giving us a selection factor for our final insertion of our new promoters.  A new promoter cassette was designed in total using oligos that encoded the two T7 promoters flanked by the same 50 base pairs of homology used previously, and inserted using recombineering into the fosmid that contained ''galK'' in the promoter region.
 +
 
 +
=Engineering the Toxin Antitoxin HSL-inducible circuit=
 +
[[Image:Washington_Building_Tse2_circuit.png|center|750px|thumb|Schematic Detailing the Transfer of Tse2 and Tsi2 from ''P. Aeruginosa'' into pSB3k3]]
 +
The Tse2/Tsi2 locus was amplified from ''P. aeruginosa'' genomic DNA using PCR. Primers were used that amplified the region from the start codon of Tse2 to the stop codon of Tsi2.  The Tse2 and Tsi2 locus was then placed downstream from F2620 via [[Team:Washington/Tools_Used/Next-Gen_Cloning|Gibson Cloning]]. Gibson cloning is a method that joins regions of homology found on the 5' and 3' ends of linearized molecules.  The end result of this Gibson cloning reaction is a circularized plasmid containing the final F2620.Tse2.Tsi2 construct in pSB3K3. The circularized plasmid is then transformed into electrocompetent ''E. coli'' Dh5a and the resulting colonies were screened for the insert of expected length via double restriction digest followed by agarose gel electrophoresis. The plasmids that showed inserts of expected length were sequenced, and it was determined that multiple plasmids had correct F2620.Tse2.Tsi2 inserts.
 +
 
 +
 
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->
<div style="text-align:center">
<div style="text-align:center">
-
'''&larr; [[Team:Washington/Project/Mougous/Design|Designing the Gram(-) Therapeutic]]'''
+
'''&larr; [[Team:Washington/Gram Negative/Design|Designing the Gram(-) Therapeutic]]'''
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
-
'''[[Team:Washington/Project/Mougous/Test|Testing the Gram(-) Therapeutic]] &rarr;'''
+
'''[[Team:Washington/Gram Negative/Test|Testing the Gram(-) Therapeutic]] &rarr;'''
</div>
</div>
{{Template:Team:Washington/Templates/Footer}}
{{Template:Team:Washington/Templates/Footer}}

Latest revision as of 16:49, 26 October 2010


Recombineering the Promoter Region of the Type VI Secretion System

Schematic Showing the Engineering of the Fosmid to Contain a Divergent T7 Promoter Instead of the Native Pseudomonas Promoter

Our goal was to replace the native P. aeruginosa regulation of the Type VI Secretion System with one that can be utilized by the E. coli transcriptional machinery. In order to replace the native promoters with more robust T7 promoters we used a technique called Recombineering to flip out the region containing both promoters and replace it with a gene cassette as follows. We designed primers to create a cassette using PCR, containing the galK galactose metabolism gene flanked by 50 base pairs of homology just outside of the promoter region in the fosmid. The cassette was inserted, giving us a selection factor for our final insertion of our new promoters. A new promoter cassette was designed in total using oligos that encoded the two T7 promoters flanked by the same 50 base pairs of homology used previously, and inserted using recombineering into the fosmid that contained galK in the promoter region.

Engineering the Toxin Antitoxin HSL-inducible circuit

Schematic Detailing the Transfer of Tse2 and Tsi2 from P. Aeruginosa into pSB3k3

The Tse2/Tsi2 locus was amplified from P. aeruginosa genomic DNA using PCR. Primers were used that amplified the region from the start codon of Tse2 to the stop codon of Tsi2. The Tse2 and Tsi2 locus was then placed downstream from F2620 via Gibson Cloning. Gibson cloning is a method that joins regions of homology found on the 5' and 3' ends of linearized molecules. The end result of this Gibson cloning reaction is a circularized plasmid containing the final F2620.Tse2.Tsi2 construct in pSB3K3. The circularized plasmid is then transformed into electrocompetent E. coli Dh5a and the resulting colonies were screened for the insert of expected length via double restriction digest followed by agarose gel electrophoresis. The plasmids that showed inserts of expected length were sequenced, and it was determined that multiple plasmids had correct F2620.Tse2.Tsi2 inserts.


Designing the Gram(-) Therapeutic       Testing the Gram(-) Therapeutic